University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders

Auld, F, Maschauer, EL, Morrison, I, Skene, Debra and Riha, RL (2016) Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders Sleep Medicine Reviews, 34. pp. 10-22.

[img]
Preview
Text
Riha accepted MS 2016.pdf - Accepted version Manuscript
Available under License : See the attached licence file.

Download (449kB) | Preview
[img]
Preview
Text (licence)
SRI_deposit_agreement.pdf
Available under License : See the attached licence file.

Download (33kB) | Preview

Abstract

Melatonin is a physiological hormone involved in sleep timing and is currently used exogenously in the treatment of primary and secondary sleep disorders with empirical evidence of efficacy, but very little evidence from randomised, controlled studies. The aim of this meta-analysis was to assess the evidence base for the therapeutic effects of exogenous melatonin in treating primary sleep disorders. An electronic literature review search of MEDLINE (1950-present) EMBASE (1980- present), PsycINFO (1987- present), and SCOPUS (1990- present), along with a hand-searching of key journals was performed in July 2013 and then again in May 2015. This identified all studies that compared the effect of exogenous melatonin and placebo in patients with primary insomnia, delayed sleep phase syndrome, Non 24- hour sleep wake syndrome in people who are blind, and REM-Behaviour Disorder. Meta-analyses were performed to determine the effect of magnitude in studies of melatonin in improving sleep. A total of 5030 studies were identified; of these citations, 13 were included for review based on the inclusion criteria of being: double or single-blind, randomised and controlled. Results from the meta-analyses showed the most convincing evidence for exogenous melatonin use was in reducing sleep onset latency in primary insomnia (p=0.002), delayed sleep phase syndrome (p<0.0001), and regulating the sleepwake patterns in blind patients compared with placebo. These findings highlight the potential importance of melatonin in treating certain first degree sleep disorders. The development of large-scale, randomised, controlled trials is recommended to provide further evidence for therapeutic use of melatonin in a variety of sleep difficulties.

Item Type: Article
Subjects : Biosciences and Medicine
Divisions : Faculty of Health and Medical Sciences > School of Biosciences and Medicine
Authors :
NameEmailORCID
Auld, FUNSPECIFIEDUNSPECIFIED
Maschauer, ELUNSPECIFIEDUNSPECIFIED
Morrison, IUNSPECIFIEDUNSPECIFIED
Skene, DebraD.Skene@surrey.ac.ukUNSPECIFIED
Riha, RLUNSPECIFIEDUNSPECIFIED
Date : 20 July 2016
Identification Number : 10.1016/j.smrv.2016.06.005
Copyright Disclaimer : © 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Uncontrolled Keywords : melatonin, sleep disorders, insomnia, delayed sleep phase syndrome, blind, REM-behaviour disorder, randomised controlled trials
Depositing User : Symplectic Elements
Date Deposited : 06 Jan 2017 14:33
Last Modified : 25 Jul 2017 08:35
URI: http://epubs.surrey.ac.uk/id/eprint/813219

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800